USPH Total Liab vs Capital Stock Analysis
USPH Stock | USD 105.45 0.49 0.47% |
US Physicalrapy financial indicator trend analysis is much more than just breaking down US Physicalrapy prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether US Physicalrapy is a good investment. Please check the relationship between US Physicalrapy Total Liab and its Capital Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.
Total Liab vs Capital Stock
Total Liab vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of US Physicalrapy Total Liab account and Capital Stock. At this time, the significance of the direction appears to have strong relationship.
The correlation between US Physicalrapy's Total Liab and Capital Stock is 0.76. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Capital Stock in the same time period over historical financial statements of US Physicalrapy, assuming nothing else is changed. The correlation between historical values of US Physicalrapy's Total Liab and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of US Physicalrapy are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Total Liab i.e., US Physicalrapy's Total Liab and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.76 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from US Physicalrapy's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into US Physicalrapy current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.As of now, US Physicalrapy's Enterprise Value Over EBITDA is increasing as compared to previous years. The US Physicalrapy's current Enterprise Value Multiple is estimated to increase to 17.58, while Selling General Administrative is projected to decrease to under 26.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 117.2M | 112.0M | 112.0M | 117.6M | Total Revenue | 495.0M | 553.1M | 604.8M | 635.0M |
US Physicalrapy fundamental ratios Correlations
Click cells to compare fundamentals
US Physicalrapy Account Relationship Matchups
High Positive Relationship
High Negative Relationship
US Physicalrapy fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 560.8M | 594.4M | 749.4M | 858.2M | 1.0B | 1.1B | |
Other Current Liab | 30.9M | 59.7M | 45.7M | 37.4M | 55.3M | 58.1M | |
Total Current Liabilities | 60.6M | 93.5M | 83.5M | 85.5M | 102.2M | 107.3M | |
Total Stockholder Equity | 240.3M | 276.2M | 295.6M | 315.8M | 476.2M | 500.0M | |
Property Plant And Equipment Net | 103.7M | 103.3M | 119.4M | 127.8M | 129.5M | 136.0M | |
Net Debt | 114.3M | 78.1M | 194.5M | 263.7M | 105.8M | 111.1M | |
Retained Earnings | 184.4M | 212.0M | 223.6M | 232.9M | 223.8M | 235.0M | |
Accounts Payable | 2.5M | 1.3M | 6.5M | 6.5M | 3.9M | 4.1M | |
Cash | 23.5M | 32.9M | 28.6M | 31.6M | 152.8M | 160.5M | |
Non Current Assets Total | 475.5M | 506.7M | 654.3M | 746.9M | 794.7M | 834.4M | |
Cash And Short Term Investments | 23.5M | 32.9M | 28.6M | 31.6M | 152.8M | 160.5M | |
Net Receivables | 56.1M | 50.9M | 62.4M | 68.6M | 71.8M | 75.4M | |
Common Stock Shares Outstanding | 12.8M | 12.8M | 12.9M | 13.0M | 14.2M | 12.9M | |
Liabilities And Stockholders Equity | 560.8M | 594.4M | 749.4M | 858.2M | 1.0B | 1.1B | |
Other Current Assets | 5.8M | 3.8M | 4.2M | 11.1M | 8.7M | 9.2M | |
Other Stockholder Equity | 55.8M | 64.0M | 71.9M | 78.7M | 249.5M | 261.9M | |
Total Liab | 181.4M | 184.4M | 297.0M | 373.6M | 375.8M | 394.6M | |
Property Plant And Equipment Gross | 103.7M | 103.3M | 97.9M | 208.0M | 214.4M | 225.1M | |
Total Current Assets | 85.4M | 87.6M | 95.2M | 111.3M | 233.4M | 245.0M | |
Short Long Term Debt Total | 137.8M | 111.0M | 223.1M | 295.3M | 258.6M | 271.5M | |
Non Currrent Assets Other | 1.5M | 1.5M | (28.7M) | (26.4M) | 158.0K | 165.9K | |
Non Current Liabilities Total | 120.8M | 90.9M | 213.5M | 288.1M | 273.7M | 287.3M | |
Short Term Debt | 27.2M | 32.4M | 31.3M | 41.6M | 42.9M | 45.1M | |
Intangible Assets | 52.6M | 56.3M | 86.4M | 108.8M | 109.7M | 115.2M | |
Good Will | 317.7M | 345.6M | 434.7M | 494.1M | 509.6M | 484.1M | |
Common Stock Total Equity | 148K | 149K | 150K | 151K | 173.7K | 144.3K | |
Common Stock | 149K | 150K | 151K | 152K | 172K | 147.0K | |
Other Assets | 1.5M | 14.1M | 1.6M | 1.6M | 1.9M | 2.1M | |
Long Term Debt | 50.4M | 16.6M | 117.6M | 175.8M | 139.0M | 145.9M | |
Property Plant Equipment | 22.1M | 21.7M | 119.4M | 127.8M | 146.9M | 154.3M | |
Other Liab | 10.2M | 12.3M | 21.7M | 34.3M | 39.5M | 41.5M | |
Net Tangible Assets | 7.7M | 6.6M | (225.5M) | (287.1M) | (258.4M) | (245.4M) | |
Noncontrolling Interest In Consolidated Entity | 930K | 1.4M | 1.5M | 1.6M | 1.4M | 1.3M | |
Retained Earnings Total Equity | 167.4M | 184.4M | 212.0M | 224.4M | 258.1M | 158.3M | |
Long Term Debt Total | 38.4M | 50.4M | 16.6M | 117.6M | 135.2M | 142.0M |
Currently Active Assets on Macroaxis
When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for USPH Stock analysis
When running US Physicalrapy's price analysis, check to measure US Physicalrapy's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy US Physicalrapy is operating at the current time. Most of US Physicalrapy's value examination focuses on studying past and present price action to predict the probability of US Physicalrapy's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move US Physicalrapy's price. Additionally, you may evaluate how the addition of US Physicalrapy to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
CEOs Directory Screen CEOs from public companies around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is US Physicalrapy's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.19) | Dividend Share 1.73 | Earnings Share 1.13 | Revenue Per Share 41.242 | Quarterly Revenue Growth 0.048 |
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.